Qiagen's QuantiFERON tuberculosis test franchise continues to displace legacy TB skin testing globally, including new US CDC guideline support. QIAstat-Dx syndromic testing competes with bioMerieux BioFire in growing infectious disease panel market. Sample technologies remain the cash generator. Post-COVID normalization has reset the base; mid-single-digit organic growth and margin expansion through automation drive consistent compounding. Sotio strategic review remains pending.
Thesis reviewed May 29, 2026
Qiagen NV is headquartered in Germany, which is currently showing moderate signals.
🇩🇪Germany51NEUTRALView Germany risk detail →🏥Healthcare33NEUTRAL| Ticker | Company | Score | Gap | Signal Δ | Action |
|---|---|---|---|---|---|
| SYK | Stryker Corporation | 36 | +15% | ↓3% | EARLY |
| TMO | Thermo Fisher Scientific Inc. | 36 | +11% | ↓3% | EARLY |
| HCA | HCA Healthcare Inc. | 36 | +9% | ↓3% | EARLY |
| CI | The Cigna Group | 36 | +9% | ↓3% | NEUTRAL |
| TEVA | Teva Pharmaceutical Industries Ltd. | 36 | +9% | ↓3% | NEUTRAL |
| ELV | Elevance Health Inc. | 36 | +7% | ↓3% | NEUTRAL |
| DHR | Danaher Corporation | 36 | +11% | ↓3% | EARLY |
Investors who hold QGEN may also have indirect exposure through these country funds.
Qiagen QuantiFERON gains US CDC update favoring IGRA over TST
QIAstat-Dx Rise platform launches with full lab automation
Estimates · Yahoo Finance · Not audited figures